GENFIT — Capital/Financing Update 2014

Jan 6, 2014

www.genfit.com

HALF-YEAR REPORT ON GENFIT'S LIQUIDITY CONTRACT WITH CM-CIC SECURITIES

Lille (France), Boston (Massachusetts, United States), January 6, 2013 – GENFIT (Alternext: ALGFT; ISIN: FR0004163111), a biopharmaceutical company at the forefront of drug discovery and development, focusing on the early diagnosis and preventive treatment of cardiometabolic and associated disorders, today announces half-year report on GENFIT's liquidity contract with CM-CIC Securities.

Under the liquidity contract entrusted by GENFIT to CM-CIC Securities, the following assets appeared on the liquidity account as at December 31, 2013:

• 16,000 shares of GENFIT, and
• 345,300.10 euros in cash.

At the implementation of the liquidity contract, the following assets appeared on the liquidity account:

• 50,000 shares of GENFIT, and
• 250,000.00 euros in cash.

About GENFIT:

GENFIT is a biopharmaceutical company focused on the Discovery and Development of drug candidates in therapeutic fields linked to cardiometabolic disorders (prediabetes/diabetes, atherosclerosis, dyslipidemia, inflammatory diseases…). GENFIT uses a multi-pronged approach based on early diagnosis, preventive solutions, and therapeutic treatments and advances therapeutic research programs, either independently or in partnership with leading pharmaceutical companies, including Sanofi, to address these major public health concerns and their unmet medical needs.

GENFIT's research programs have resulted in the creation of a rich and diversified pipeline of drug candidates at different stages of development, including GENFIT's lead proprietary compound, GFT505, that is currently in Phase IIb.

With facilities in Lille, France, and Cambridge, MA (USA), the Company has approximately 80 employees. GENFIT is a public company listed on the Alternext trading market by Euronext™ Paris (Alternext: ALGFT; ISIN: FR0004163111). www.genfit.com

Contacts:

GENFIT Jean-François Mouney – CEO & Chairman of the Management Board Ph. +333 2016 4000

MILESTONES – Press Relations

Bruno Arabian Ph. +331 7544 8740 / +336 8788 4726 – barabian@milestones.fr